ONCY

0.772

2.89% -0.023

Dopo l'orario di chiusura: .76 -0.012 -1.55%

Oncolytics Biotech Inc (ONCY)

Panoramica Notizia Cronologia dei prezzi Perché ONCY Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$0.795

Aprire:

$0.7933

Volume 24 ore:

3.73M

Relative Volume:

3.26

Capitalizzazione di mercato:

$98.44M

Reddito:

Utile/perdita netta:

$-25.91M

Rapporto P/E:

-3.0671

EPS:

-0.2517

Flusso di cassa netto:

$-22.73M

1 W Prestazione:

-9.87%

1M Prestazione:

-3.84%

6M Prestazione:

-24.31%

1 anno Prestazione:

-41.07%

Intervallo 1D:

$0.76

$0.8274

Intervallo di 1 settimana:

$0.76

$0.8522

Portata 52W:

$0.7301

$1.51

Oncolytics Biotech Inc Stock (ONCY) Company Profile

Nome

Oncolytics Biotech Inc

Settore

Healthcare (1069)

Industria

Biotechnology (595)

Telefono

(403) 670-7377

Indirizzo

SUITE 325, 4350 EXECUTIVE DRIVE, SAN DIEGO, AB

Dipendente

Cinguettio

@oncolytics

Prossima data di guadagno

2026-08-14

Ultimi documenti SEC

ONCY's Discussions on Twitter

Compare ONCY vs VRTX, REGN, ARGX, MRNA, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ONCY Oncolytics Biotech Inc	0.772	101.37M	0	-25.91M	-22.73M	-0.2517
VRTX Vertex Pharmaceuticals Inc	514.56	132.08B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	793.26	83.15B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	984.04	62.71B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	136.62	54.14B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	203.35	44.51B	742.00K	-1.37B	-1.07B	-7.0731

Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-08-13	Iniziato	Lake Street	Buy
2022-10-06	Iniziato	Maxim Group	Buy
2021-02-17	Iniziato	H.C. Wainwright	Buy

Oncolytics Biotech Inc Borsa (ONCY) Ultime notizie

10:15 AM

Oncolytics Biotech Inc - Baystreet.ca

10:15 AM

09:28 AM

Oncolytics (ONCY) Reports Promising Preclinical Data on Pelareor - GuruFocus

09:28 AM

08:53 AM

Oncolytics reports preclinical data on pelareorep with RAS inhibitor - Investing.com

08:53 AM

08:31 AM

Oncolytics reports preclinical data on pelareorep with RAS inhibitor By Investing.com - Investing.com India

08:31 AM

08:15 AM

Oncolytics Biotech® Announces Positive Preclinical Results - GlobeNewswire

08:15 AM

08:06 AM

12 Health Care Stocks Moving In Thursday's Pre-Market Session - benzinga.com

08:06 AM

Sep 04, 2026

Oncolytics Biotech Inc.ADR Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com

Sep 04, 2026

Sep 02, 2026

Zacks Research Issues Pessimistic Forecast for ONCY Earnings - MarketBeat

Sep 02, 2026

Aug 27, 2026

3 Small Cap Biotech Stocks Trading At A Discount With Late Stage Clinical Catalysts - Sahm

Aug 27, 2026

Aug 26, 2026

Could Oncolytics Biotech (TSX:ONC) Reach Its Next Clinical Milestone? - Kalkine Media

Aug 26, 2026

Aug 21, 2026

Oncolytics Biotech (NASDAQ:ONCY) Price Target Cut to $5.00 by Analysts at HC Wainwright - MarketBeat

Aug 19, 2026

H.C. Wainwright cuts Oncolytics Biotech price target to $5 on pipeline shift - Investing.com Canada

Aug 19, 2026

H.C. Wainwright Maintains Oncolytics Biotech(ONCY.US) With Buy Rating, Cuts Target Price to $5 - Moomoo

Aug 19, 2026

symbol__ Stock Quote Price and Forecast - CNN

Aug 19, 2026

Why Oncolytics Biotech Just Cleared A Hurdle That Stalls Most Cancer Trials - Yahoo Finance

Aug 19, 2026

Aug 18, 2026

BRIEF-Oncolytics Biotech® Aligns With FDA On Registrational Path For Second-Line Ras-Mutant Mss Colorectal Cancer - Bitget

Aug 18, 2026

Oncolytics Biotech (ONCY) Advances Pelareorep Trial with Positiv - GuruFocus

Aug 18, 2026

Stocks in play: Oncolytics Biotech Inc - Barchart.com

Aug 18, 2026

Form 8K Oncolytics Biotech Inc. For: 18 August By Investing.com - Investing.com Nigeria

Aug 18, 2026

Oncolytics receives FDA feedback on colorectal cancer study design - Investing.com

Aug 18, 2026

Oncolytics receives FDA feedback on colorectal cancer study design By Investing.com - Investing.com Canada

Aug 18, 2026

Oncolytics aligns with FDA on potential pivotal expansion of REO 033 in RAS‑mutant MSS colorectal cancer - TradingView

Aug 18, 2026

Oncolytics may seek accelerated approval using tumor response data - Stock Titan

Aug 18, 2026

Aug 17, 2026

ONCY Stock Heads For Sixth Straight Session Of Gains – Lead Therapy Shines in Early Combination Treatment Study - Stocktwits

Aug 17, 2026

Aug 16, 2026

Oncolytics Biotech (ONCY) Climbs 4.25% to $0.83 as Small-Cap Biotech Finds BuyersRetracement Entry - vinanet.vn

Aug 16, 2026

Aug 15, 2026

ONCY Q3 2025 Earnings: Wider Loss Misses Estimates, Stock Still Rises 4.25%Cost Structure Review - vinanet.vn

Aug 15, 2026

Aug 14, 2026

ONCY News | ONCOLYTICS BIOTECH INC (NASDAQ:ONCY) - ChartMill

Aug 14, 2026

Aug 13, 2026

Oncolytics Biotech (ONCY) Holds Near $0.82 as Shares Edge Up 0.49%Entry Point Alerts - vinanet.vn

Aug 13, 2026

Aug 12, 2026

Oncolytics Biotech (NASDAQ:ONCY) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat

Aug 12, 2026

ONCY: Net loss increased to $9.4M in Q2 2026, with cash needs exceeding current resources - TradingView

Aug 12, 2026

Oncolytics net loss widens to $9.44 million in Q2 2026; R&D expenses more than doubled to $4.26 million - Bitget

Aug 12, 2026

Aug 10, 2026